Martin Shkreli accused of violating lifetime ban from pharmaceutical industry

Martin Shkreli, a former pharmaceutical executive notorious for hiking the price of an anti-parasitic drug by over 4,000 percent and subsequently serving a seven-year prison sentence for his fraudulent scheme, has been accused of violating a lifetime ban from the industry.

According to allegations made by the Federal Trade Commission (FTC) and attorneys general of seven states, Shkreli repeatedly disregarded the ban by engaging in stock trading activities with dozens of pharmaceutical companies and discussing the industry on social media livestreams. The FTC and state officials claim that these actions demonstrate a blatant disregard for the law.

The alleged violations took place despite Shkreli's 2022 lifetime ban from the pharmaceutical industry, which was imposed after he engaged in an "elaborate anticompetitive scheme" involving the anti-parasitic drug Daraprim. The price of this life-saving medication was hiked from $17.50 per pill to $750 per pill within a short period.

The FTC and seven states - New York, California, Illinois, North Carolina, Ohio, Pennsylvania, and Virginia - have now asked a federal judge to hold Shkreli in contempt for the alleged violations. This latest development marks another chapter in the ongoing saga surrounding Shkreli's activities in the pharmaceutical industry.

The FTC and state regulators have accused Martin Shkreli of violating a lifetime ban on participating in the pharmaceutical industry.

As part of this alleged misconduct, Shkreli is said to have traded shares in various pharmaceutical companies despite being barred from doing so under the terms of his lifetime ban.

Regulators are now seeking to force Shkreli to sell off all his stakes in pharmaceutical companies and pay a fine equal to the profits he made from trading these stocks.

In addition to financial penalties, the FTC and state regulators want the court to establish clear consequences for future breaches of the ban, including increased fines and potential incarceration.

The FTC has filed a brief outlining four phases of alleged violations by Martin Shkreli of his lifetime ban on pharmaceutical industry involvement.

Shkreli's activities in question include participating in online trading competitions and challenges, where he would often discuss and showcase his trades to his audience.

In these livestreams, Shkreli frequently displayed his investment accounts on screen and provided detailed analysis of pharmaceutical companies, including predictions about the outcomes of clinical trials.

He also shared his strategy for profiting from shorting biotech stocks, claiming that he could "smoke them by identifying undervalued companies.

The FTC and state regulators have discovered evidence of Martin Shkreli's continued involvement in the pharmaceutical industry despite his lifetime ban. They claim that stocks discussed during his livestreams are just a small sample of his activities.

Shkreli has revealed that he maintains other accounts on social media, but is hesitant to share them due to concerns about being monitored by law enforcement, as he stated I have some other accounts that I'd show you, but, like, I know feds are watching, so f[*]ck that".